Horizon Therapeutics (HZNP) Misses Q1 EPS by 13c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Horizon Therapeutics (HZNP) Tepezza is Now Underway, Add Stock - Cowen
May 5, 2021 11:30 AM EDTCowen analyst Ken Cacciatore reiterated an Outperform rating and $120.00 price target on Horizon Therapeutics (NASDAQ: HZNP) following Q1 results with the resupply of Tepezza is now underway.
The analyst commented, "We have never encountered a product that launched and within three... More



